Anhui Zhifei Longcom Biopharmaceutical

Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. appears in Chongqing Zhifei Biological Products Co., Ltd.'s official material as one of its subsidiaries and as a new high-tech enterprise. Wikidata classifies the entity as a biotech company. The supplied evidence does not provide further verified details about this entity's own history, ownership, leadership, products, or operations.

Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. is a new high-tech enterprise and a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd. ("Zhifei"), a Chinese vaccine company that entered the biological products industry in 2002. Zhifei describes itself as a high-tech biological enterprise integrating research and development, production, marketing, distribution, and import and export, with a focus on vaccines for human use. In September 2010, Zhifei was listed on the Shenzhen Stock Exchange under stock code 300122, becoming the first privately run vaccine enterprise listed on ChiNext. The parent company operates through five wholly-owned subsidiaries and a joint-stock subsidiary; Anhui Zhifei Longcom Biopharmaceutical and Beijing Zhifei Lvzhu Biopharmaceutical are identified as new high-tech enterprises within the group. Anhui Zhifei Longcom Biopharmaceutical is associated with the development and production of recombinant vaccine and diagnostic products, including the Recombinant Novel Coronavirus Vaccine (CHO Cell) and the Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (Ekear®), which are listed among Zhifei's commercially available products. The company forms part of Zhifei's vaccine portfolio, which also includes Haemophilus Influenzae Type b Vaccine (XiFeiBei®), Group ACYW 135 Meningococcal Polysaccharide Vaccine (Menwayc®), Mycobacterium Vaccae for Injection (Vaccae®), and Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine (Mening A Con®).

• 2021

  Zhifei reports operating income of RMB 13.2 billion in the first half of 2021, supported by nearly 4,500 employees.

• 2010

  Zhifei lists on the Shenzhen Stock Exchange (stock code: 300122), becoming the first privately run vaccine enterprise listed on ChiNext.

• 2002

  Chongqing Zhifei Biological Products Co., Ltd. enters the biological products industry.

• Recombinant Novel Coronavirus Vaccine (CHO Cell)

  A vaccine that stimulates the body to produce immunity against novel coronaviruses and is used to prevent diseases caused by novel coronavirus infections.

• Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (Ekear®)

  A product applicable to the diagnosis of Mycobacterium tuberculosis infection; skin test results are not affected by BCG vaccination and can be used to assist the clinical diagnosis of tuberculosis.

• Group A and Group C Meningococcal Polysaccharide Vaccine

  A preparation of purified capsular polysaccharide antigens extracted from cultures of Neisseria meningitidis group A and C, lyophilized after addition of lactose.

• ACYW135 Meningococcal Polysaccharide Vaccine

  A preparation of purified capsular polysaccharide antigens extracted from cultures of Neisseria meningitidis group A, C, Y and W135, lyophilized after addition of a stabilizer.

• Haemophilus Influenzae Type b Conjugate Vaccine

  A preparation of purified capsular polysaccharide of Haemophilus influenzae type b covalently bound to tetanus toxoid and adsorbed with aluminum phosphate adjuvant.

1. 1Chongqing Zhifei Biological Products Co.,Ltd. - About Zhifeien.zhifeishengwu.com
2. 2Wikidata - Anhui Zhifei Longcom Biopharmaceuticalwikidata.org
3. 3Chongqing Zhifei Biological Products Co.,Ltd. - Productsen.zhifeishengwu.com
4. 4Chongqing Zhifei Biological Products Co.,Ltd. - Corporate Cultureen.zhifeishengwu.com
5. 5Chongqing Zhifei Biological Products Co.,Ltd.en.zhifeishengwu.com